WWM
TGTX icon

Willingdon Wealth Management’s TG Therapeutics TGTX Stock Holding History

Willingdon Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$0 Hold
4
– – ﹤0.01% 383
2019
Q4 		$0 Hold
4
– – ﹤0.01% 525
2019
Q3 		$0 Hold
4
– – ﹤0.01% 539
2019
Q2 		$0 Hold
4
– – ﹤0.01% 358
2019
Q1 		$0 Hold
4
– – ﹤0.01% 397
2018
Q4 		$0 Hold
4
– – ﹤0.01% 406
2018
Q3 		$0 Hold
4
– – ﹤0.01% 421
2018
Q2 		$0 Hold
4
– – ﹤0.01% 352
2018
Q1 		$0 Hold
4
– – ﹤0.01% 386
2017
Q4 		$0 Hold
4
– – ﹤0.01% 371
2017
Q3 		$0 Buy
+4
New +$46 ﹤0.01% 307

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Willingdon Wealth Management's TGTX Position: Q1 2020 in Review

Willingdon Wealth Management held its TG Therapeutics (TGTX) position steady in Q1 2020 at 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #383.

Willingdon Wealth Management first reported a position in TGTX in Q3 2017 and has held it in 11 quarters since. 146 funds tracked by Wall St. Rank hold TGTX as of Q1 2020.

  • Willingdon Wealth Management held 4 shares of TG Therapeutics worth $0 as of Q1 2020.
  • Willingdon Wealth Management left its TG Therapeutics share count unchanged in Q1 2020.
  • TG Therapeutics made up ﹤0.01% of Willingdon Wealth Management's portfolio in Q1 2020, its #383 holding.
  • Willingdon Wealth Management first reported a position in TG Therapeutics in Q3 2017 and has held it in 11 quarters since.
  • 146 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2020.

Based on Willingdon Wealth Management's 13F filing for Q1 2020, filed 21 Apr 2020.